No Data
No Data
Insulet Tops S&P 500 Growth Chart for Q2 as It Gains Market Share in the Diabetes Space
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $240
Form 144 | Insulet(PODD.US) Insider Proposes to Sell 4.07 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Jun 25, $Insulet(PODD.US)$ Insider Petrovic Shacey intends to sell 20,000 shares of its common stock on Jun 25, with a total market value of approximately $4.07 million. Sou
Insulet Points Its Insulin Pump at the Big Diabetes Market: Type 2 -- Barrons.com
Is weight loss medicine or stock market bomb? Eli Lilly and Co's new drug tirzepatide caused a sharp drop in sleep device stocks.
The recent clinical trial results of the new weight loss drug tirzepatide have not only caused a sensation in the medical community, but also stirred up waves in the stock market.
Lilly Weight-Loss Drug Data Spurs Selloff in Sleep Apnea Stocks